Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
Veracyte to present data demonstrating potential of Envisia Genomic Classifier to improve ILD diagnosis

Veracyte to present data demonstrating potential of Envisia Genomic Classifier to improve ILD diagnosis

Study reveals long-term safety, efficacy of Ofev in patients with idiopathic pulmonary fibrosis

Study reveals long-term safety, efficacy of Ofev in patients with idiopathic pulmonary fibrosis

Cedars-Sinai receives $12 million from NIH to investigate deadly lung conditions

Cedars-Sinai receives $12 million from NIH to investigate deadly lung conditions

UA researchers receive $4.4 million grant to focus on idiopathic pulmonary fibrosis

UA researchers receive $4.4 million grant to focus on idiopathic pulmonary fibrosis

New guideline developed to help physicians diagnose idiopathic pulmonary fibrosis

New guideline developed to help physicians diagnose idiopathic pulmonary fibrosis

UAB receives NIH grant to continue evaluation of new medication for IPF

UAB receives NIH grant to continue evaluation of new medication for IPF

Scleroderma Foundation names Tulane professor as 'Doctor of the Year'

Scleroderma Foundation names Tulane professor as 'Doctor of the Year'

Gene therapy with telomerase does not increase cancer risk, study shows

Gene therapy with telomerase does not increase cancer risk, study shows

Penn researchers develop first mouse model of idiopathic pulmonary fibrosis

Penn researchers develop first mouse model of idiopathic pulmonary fibrosis

Scientists uncover mechanisms responsible for development of fibrosis

Scientists uncover mechanisms responsible for development of fibrosis

Established lung fibrosis can be reversed using diabetes drug treatment

Established lung fibrosis can be reversed using diabetes drug treatment

Researchers identify culprit that spurs damaging inflammation following heart attack

Researchers identify culprit that spurs damaging inflammation following heart attack

Lung-on-a-chip technology could streamline drug-testing for pulmonary fibrosis

Lung-on-a-chip technology could streamline drug-testing for pulmonary fibrosis

Researchers uncover the cause of scarring in idiopathic pulmonary fibrosis

Researchers uncover the cause of scarring in idiopathic pulmonary fibrosis

Experimental compound reduces destructive inflammation to improve stroke outcome

Experimental compound reduces destructive inflammation to improve stroke outcome

Scientists find new molecular target to treat idiopathic pulmonary fibrosis

Scientists find new molecular target to treat idiopathic pulmonary fibrosis

Dentists mysteriously succumbing to lung disease finds the CDC

Dentists mysteriously succumbing to lung disease finds the CDC

ASU researchers uncover crucial step in telomerase enzyme catalytic cycle

ASU researchers uncover crucial step in telomerase enzyme catalytic cycle

Researchers develop gene therapy for idiopathic pulmonary fibrosis

Researchers develop gene therapy for idiopathic pulmonary fibrosis

Researchers use gene therapy that lengthens telomeres to cure pulmonary fibrosis in mice

Researchers use gene therapy that lengthens telomeres to cure pulmonary fibrosis in mice